CVD preventive interventions WORKSHOP Jurate Klumbiene Kaunas University of Medicine, Kaunas, Lithuania.

Slides:



Advertisements
Similar presentations
Cardiovascular Risk Assessment
Advertisements

DO YOU HAVE THE METABOLIC SYNDROME? You're never too young to have it Jacqueline A. Eberstein, R.N.
EUROACTION: Changes in diet and physical activity over one year in a family based preventive cardiology programme in hospital and general practice Jennifer.
« Systematic Cerebrovascular and cOronary Risk Evaluation » Global Cerebrovascular Risk Assessment SCORE - Canada « Systematic Cerebrovascular and cOronary.
U.S. Dept of Health and Human Services. National High Blood Pressure Education Program. Seventh Report of Joint National Committee on Prevention, Detection,
The Healthy Heart Figure 14.1.
CVD risk estimation and prevention: An overview of SIGN 97.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
COHORH STUDY A research paper on BMJ. What is cohort study? Investigates from exposure to outcome, in a group of patients without, or with appropriate.
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
European Guidelines on CVD prevention ESC Commitee für Practice Guidelines to improve the quality of clinical practice and patient care in Europe Fourth.
Childe Hassam: “The South Ledges” Early 20 th Century American Impressionist: Note: light And color! (Very European…)
ADVICE. Advice Strongly advise adherence to diet and medication Smoking cessation, exercise, weight reduction Ensure diabetes education and advise Diabetes.
Effectiveness of interactive web-based lifestyle program on prevention of cardiovascular diseases risk factors in patient with metabolic syndrome: a randomized.
BHS Guidelines for the management of hypertension BHS IV, 2004 and Update of the NICE Hypertension Guideline, 2006 Guidelines for management of hypertension:
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Understanding blood lipids and glucose How a Healthy Lifestyle can improve your numbers Susan Fullmer, PhD RD Associate Teaching Professor Nutrition, Dietetics,
Cardiovascular Disease in Women Module III: Risk Assessment Tool.
LIFESTYLE MODIFICATIONS FOR PREVENTING HEART DISEASE [e.g. HEART ATTACKS] [ primary prevention of coronary artery disease ] DR S. SAHAI MD [Med.], DM [Card]
What is Diabetes? Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively.
Prof. Jaakko Tuomilehto Department of Public Health University of Helsinki, Department of Epidemiology and Health Promotion National Public Health Institute.
Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.
What is Diabetes?.
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
MI: Risk Factors and Primary Prevention. Risk Factors Factors that appear to increase the general population’s chances of experiencing a health problem.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
Nutrition and Cardiovascular Disease. Cardiovascular Disease Includes heart attack, stroke Includes heart attack, stroke Leading cause of death in the.
December Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation?
RISK FACTOR FOR CORONARY ARTERY DISEASE
METABOLIC Syndrome: a Global Perspective
Chapter 10: Special Topics in Adults & Chronic Diseases: Nutrition and Public Health Judith Sharlin, PhD, RD.
Risk factors to the Cardiovascular System. Learning Outcomes Describe modifiable risk factors: diet, smoking, activity, obesity Describe non-modifiable.
CARDIOVASCULAR DISEASE The Nature of CVD Extent and Trend of CVD Risk factors Social determinants High Risk Groups.
0CTOBER 2010 An Approach for Sub-Saharan Africa. Dr. Linda Hawker, MD, CCFP General Practice Kelowna BC Canada.
1 Hypertension Overview. 2 Leading Risks For Death (World Health Organization 2002) Cholesterol Alcohol HYPERTENSION Tobacco use Overweight.
10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.
Blood pressure control in primary health care WORKSHOP
Risk Factors for Cardiovascular Disease
CARDIOVASCULAR DISEASE (CVD)
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Studying mortality trends: The IMPACT CHD Policy Model
International Guidelines for Prevention of Atherosclerotic Cardiovascular Disease Prof. Mohamed Sobhy, MD, FACC Professor of Cardiology, Alex. University.
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
Lowering Your Cholesterol University Medical Center Community Education Program.
Section III. Assessment of Overall Cardiovascular Risk in Hypertensive Patients 2015 Canadian Hypertension Education Program Recommendations.
Polypill x Aspirin Project Groups 3 and 4
Definition of the ‘health transition’ Trends of disease patterns in populations The 4 stages of the epidemiological transition The cardiovascular disease.
An aortic aneurysm can rupture (dissecting aneurysm) and cause massive blood loss, circulatory shock and rapid death.
MACROVASCULAR COMPLICATIONS, DYSLIPIDEMIA and HYPERTENSION 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Laboratory Testing For Cardiovascular Risk
Results of 12 month follow up in Tulppa outpatient rehabilitation program.
EU Heart Group Brussels 2 October 2007 Fourth Joint European Societies’ Task Force on cardiovascular disease prevention in clinical practice Ian Graham,
Objectives of Training To provide you with an overview of MSD Informatics Software. To provide you with sufficient training to be able to use MSD Informatics.
NHS Health Check programme An opportunity to engage 15 million people to live well for longer Louise Cleaver National Programme Support Manager.
Case 1: Elevated LDL-C in a Young Adult. Page 2 of 10 *DALY; disability-adjusted life years Routine checkup:  Age:33 years  Sex: male  Status: Except.
Presented by Slyter Nutrition Consulting Services.
Alcohol, Other Drugs, and Health: Current Evidence July–August 2017
Prevention Diabetes.
Hypertension Hanna K. Al-Makhamreh, MD FACC Interventional Cardiology.
Diabetes Health Status Report
Prevention Cardiovascular disease
Progress and Promise in RAAS Blockade
Prevention Diabetes Dr Abir Youssef 29/11/2018.
Developing a Heart-Healthy Life Style
1 Physical Activity, Health, and Chronic Disease chapter 1 chapter
Chapter 7 LIPIDS IN HEALTH & DISEASE
Goals & Guidelines A summary of international guidelines for CHD
Presentation transcript:

CVD preventive interventions WORKSHOP Jurate Klumbiene Kaunas University of Medicine, Kaunas, Lithuania

Objectives of the workshop To broaden an understanding of the differences in the main strategies in prevention of CVD To improve skills in planning and conducting preventive activities To update knowledge concerning approaches to CVD management

Agenda of the workshop Practice profile - presentation Identification of potential interventions using population, high-risk strategies and secondary prevention of CVD – group work Group work results – presentation The main strategies of CVD prevention - lecture

Practice description I. General profile Country region – industrial (coal mines, steel factories) Urban setting – city with 200,000 inhabitants Localization – in the city centre with easy access by public transportation Type of practice - single Practice population – 2,356 individuals (638 children under 18, 472 persons over 65) Staff – 1 physician, 2 community nurses, 1 practice nurse, 1 part-time midwife Reimbursement system – public insurance, per capita Disease registers – unavailable Medical records – traditional paper forms

Practice description II. Lifestyle habits The nutrition survey conducted on a random sample of the practice population obtained the following data: total fat intake accounted for 45% of energy intake, saturated fats intake for 15 %; the average intake of cholesterol was 380 mg/day; 25 % of people consumed fruits and vegetables daily. 520 males and 356 of females are smokers. A sedentary lifestyle is common for the population.

Practice description III. Persons with risk factors for CVD 773 with hypertension 810 with high serum cholesterol 346 who are obese and 515 who are overweight 315 males and 200 women are regular smokers

Practice description IV. Patients with CVD Stroke – 35 patients History of MI – 27 patients Angina pectoris – 29 patients Atrial fibrillation – 24 patients Heart failure – 19 patients

Tasks for group work Prepare a comprehensive plan of preventive activities in the field of CVD using the following strategies: 1)Population strategy 2)High-risk strategy 3)Secondary prevention

Presentation of group work results – plenary discussion

The main strategies of CVD prevention (a lecture based on the European guidelines on cardiovascular disease prevention in clinical practise, 2007)

THE RATIONALE FOR AN ACTIVE APPROACH TO THE PREVENTION OF CARDIOVASCULAR DISEASES CVD is the major cause of premature death in most European populations. The underlying pathology is usually atherosclerosis. Death, myocardial infarction and stroke nevertheless frequently occur suddenly and before medical care is available. The mass occurrence of CVD relates strongly to life- styles and modifiable physiological factors. Risk factor modifications have been shown to reduce CVD mortality and morbidity, particularly in high-risk subjects.

CVD PRIMARY PREVENTION Population strategy - for altering, in the entire population, those lifestyle and environmental factors, and their social and economic determinants, that are the underlying causes of the mass occurrence of CVD High-risk strategy - identification of high-risk individuals and action to reduce their risk factor levels

CVD SECONDARY PREVENTION The prevention of recurrent CVD events and the progression of the disease in patients with established cardiovascular organ damage or disease.

THE PRIORITIES FOR CVD PREVENTION 1. Patients with established atherosclerotic CVD. 2.Asymptomatic individuals who are at high risk of developing CVD because of: a) multiple risk factors resulting in a 10 year risk of ≥ 5% now (or if extrapolated to age 60) for developing a fatal CVD event b) markedly raised levels of single risk factors: cholesterol ≥ 8 mmol/l, LDL cholesterol ≥ 6 mmol/l, blood pressure ≥ 180/110 mmHg c) diabetes type 2 and diabetes type 1 with micro- albuminuria 3.Close relatives (first-degree relatives) of a) patients with early onset atherosclerotic CVD b) asymptomatic individuals at particularly high risk

OBJECTIVES OF CVD PREVENTION 1. To assist those at low risk of CVD to maintain this state for their entire lives and to help those at increased total CVD risk to reduce it.

OBJECTIVES OF CVD PREVENTION 2. To achieve the characteristics of people who tend to stay healthy: -Nonsmoking -Healthy food choices -Physical activity: 30 min. of moderate activity a day -BMI < 25 kg/m 2 -BP < 140/90 mmHg -Total cholesterol < 5 mmol/l -LDL cholesterol < 3 mmol/l -Blood glucose < 6 mmol/l

OBJECTIVES OF CVD PREVENTION 3. To achieve more rigorous risk factor control over high-risk subjects, especially those with established CVD and diabetes: - BP < 130/80 mmHg if feasible - Total cholesterol < 4.5 mmol/l including those with < 4mmol/l if feasible - LDL cholesterol < 2.5 mmol/l including those with < 2mmol/l if feasible - Fasting blood glucose < 6 mmol/l

OBJECTIVES OF CVD PREVENTION 4. To consider cardioprotective drug therapy in high-risk subjects, especially those with established atherosclerotic CVD.

THE SCORE RISK ASSESSMENT SYSTEM (HeartScore, at Based on a large dataset of 12 European cohort studies Predicts fatal CVD events over a 10-year period Integrated the following risk factors: - gender - age - smoking - systolic BP - cholesterol (the cholesterol, cholesterol/HDL ratio) The threshold for being at high risk is defined as ≥ 5%

RISK CHART FOR LOW-RISK COUNTRIES

RISK CHART FOR HIGH-RISK COUNTRIES

THE DEFINITION OF HIGH TOTAL RISK FOR DEVELOPING A FATAL CARDIOVASCULAR EVENT 1. Patients with established cardiovascular disease 2. Asymptomatic subjects who have: 2.1. Multiple risk factors resulting in a 10 year risk ≥ 5% now or if extrapolated to age Markedly raised levels of single risk factors: total cholesterol ≥ 8 mmol/l, LDL cholesterol ≥ 6 mmol/l, blood pressure ≥ 180/110 mmHg 2.3.Diabetes type 2 and diabetes type 1 with microalbuminuria

CVD RISK MAY BE HIGHER THAN INDICATED IN THE CHART FOR: Sedentary or obese subjects, especially those with central obesity. Asymptomatic subjects with pre-clinical evidence of atherosclerosis (e.g. CT scan, ultrasonography). Subjects with a strong family history of premature CVD. Subjects with low HDL cholesterol or high triglycerides. Subjects with diabetes – a fivefold higher risk in women with diabetes & a threefold higher risk in men with diabetes compared with those without diabetes. The socially deprived.

THE METABOLIC SYNDROME The term refers to the combination of several factors that tend to cluster together in central obesity – hypertension, low HDL cholesterol, raised triglycerides, and raised blood glucose – to increase risk of diabetes and CVD. This implies that, if one component is identified, a systematic search for others is indicated, together with an active approach to managing all of these factors. Physical activity and weight control can radically reduce the risk of developing diabetes in those with the metabolic syndrome.

RELATIVE RISK CHART

THE MANAGEMENT OF CVD RISK IN CLINICAL PRACTICE Behavioural risk factors - stop smoking tobacco - make healthy food choices - increase physical activity Management of other risk factors - being overweight and obesity - blood pressure - plasma lipids - diabetes - metabolic syndrome

CARDIOPROTECTIVE DRUG THERAPY Aspirin for virtually everyone with established CVD and for persons with >10% SCORE risk once blood pressure has been controlled.  blockers after myocardial infarction and, in carefully titrated doses, in those with heart failure. ACE inhibitors for those with left ventricular dysfunction and in diabetic subjects with hypertension or nephropathy. Anticoagulants in those at increased risk of thromboembolic events, particularly atrial fibrillation.